Are Orthobiologics Transforming Bone and Cartilage Treatment?

The field of orthobiologics market is witnessing unprecedented growth, driven by cutting-edge regenerative medicine technologies and strategic business developments. Orthobiologics, which include products derived from biologic substances to support bone and cartilage repair, are rapidly gaining adoption in hospitals and clinics worldwide. From autologous cellular therapies to advanced allograft solutions, the sector is becoming a cornerstone of modern orthopedic care.

Keensight Capital and Isto Biologics: Expanding Regenerative Capabilities

In September 2025, Keensight Capital acquired a majority stake in Isto Biologics, a U.S.-based regenerative MedTech company, from Thompson Street Capital Partners. Isto Biologics, founded in 2016, specializes in orthobiologic products designed to accelerate bone healing. Its portfolio spans six functional areas of bone graft solutions, including advanced allografts used extensively in spinal surgeries. The company currently serves over 400 hospitals and clinics, performing approximately 15,000 surgical procedures per month in the United States.

With Keensight Capital’s support, Isto aims to expand globally, leveraging its expertise in biomaterials for tissue regeneration. Keensight’s extensive experience in orthopedics and spine markets positions Isto to accelerate both organic growth and acquisition-led expansion. Isto Biologics’ partnership with Keensight Capital demonstrates the growing investor confidence in orthobiologics and highlights the global expansion potential of regenerative bone therapies.

Octane Medical Acquires B. Braun’s Orthobiologics Business

In June 2024, Octane Medical Group acquired B. Braun’s global orthobiologics business, including TETEC AG in Germany and Aesculap Biologics, LLC in the United States. This acquisition consolidates Octane’s position as an international leader in regenerative medicine.

The platform includes two advanced therapies. NOVOCART 3D is a collagen-based matrix scaffold implanted with cartilage cells to repair damaged tissue, while NOVOCART Inject is an injectable mixture of cartilage cells and PEG-albumin-hyaluronic acid hydrogel for targeted cartilage repair.

Additionally, Octane plans to integrate its automated Cocoon bioreactor system to scale up production of these therapies. This approach will increase consistency, reduce costs, and expand global accessibility, positioning Octane to offer turnkey regenerative solutions across North America and Europe. Octane’s acquisition underscores the critical role of automation and scalable manufacturing in meeting rising demand for orthobiologic therapies.

Harnessing Biological Potential: The Growth of the Global Orthobiologics and Artificial Tissue Market

The core mechanisms of stem cells within the field of orthobiologics, a sector where companies like Isto Biologics and Octane Medical specialize. At the center of the diagram is a multipotent stem cell, which serves as a biological powerhouse for tissue repair and regeneration.

One primary function shown is the ability to reduce inflammation, which is vital for treating joint injuries and chronic conditions like osteoarthritis. The cell also works to fight apoptosis, or programmed cell death, by releasing signals that protect surrounding healthy tissue from further damage. Another critical capability is self-replication, allowing the body to maintain a steady supply of these regenerative cells at the site of an injury. Perhaps most importantly, the diagram shows how these cells can differentiate into specialized tissues. This process allows them to transform into muscle, bone, fat, or cartilage depending on the specific needs of the patient's body.

As highlighted in the news regarding Keensight Capital’s investment in Isto Biologics and Octane Medical’s acquisition of B. Braun’s global business, the industry is increasingly focused on these biological solutions. Rather than relying solely on traditional metal hardware for orthopedic surgery, these companies develop technologies that leverage these natural cellular processes to heal fractures and repair soft tissue.

Why Orthobiologics Are Gaining Momentum

Orthobiologics are gaining traction due to several converging factors. Therapies are designed to accelerate healing and improve functional recovery after orthopedic procedures. Integration of cellular therapies, scaffolds, and bioreactors allows precision in tissue repair. Hospitals are increasingly adopting these solutions, with Isto Biologics performing over 15,000 procedures per month. Strategic acquisitions and partnerships, such as those executed by Octane and Isto, are enabling companies to scale both technologically and geographically.

Key Players Drive Innovation in the Orthobiologics Market

The orthobiologics market features several prominent players, including Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Group, Inc., Integra LifeSciences Holdings Corporation, Arthrex, Inc., Johnson & Johnson (J&J), Exactec Inc., Medline Industries, Inc., Globus Medical, Inc., and NuVasive Inc. These companies are actively strengthening their market positions through the launch of innovative products. Zimmer Biomet Holdings, Inc. unveiled the Persona Revision Knee System for knee replacement surgeries. This advanced revision system features an intuitive instrumentation platform that allows surgeons to tailor their approach to both simple and complex procedures while providing anatomical components for a personalized patient fit.

Next Move Strategy Consulting’s View

According to Next Move Strategy Consulting it notes that the orthobiologics sector is moving from niche adoption to mainstream orthopedic care, fueled by evidence-based outcomes and patient demand for faster recovery. Strategic acquisitions and partnerships are key drivers of international growth, enabling companies to scale advanced technologies rapidly. Furthermore, automation in production is crucial to maintaining quality and reducing costs for personalized cell therapies. Orthobiologics are no longer experimental; they are becoming essential solutions in orthopedic and regenerative medicine, supported by both strategic business investments and technological innovation.

Next Steps: Actionable Insights

• Healthcare providers should explore partnerships with orthobiologic manufacturers to expand access to advanced bone and cartilage repair solutions.

• Investors should monitor strategic acquisitions like Isto Biologics and Octane Medical for growth opportunities in regenerative medicine.

• Regulators and policymakers should support frameworks that ensure quality and safety in automated and cell-based therapy production.

• Medical technology companies should invest in scalable manufacturing platforms and bioreactor technologies to reduce costs and improve global reach.

• Researchers and clinicians should conduct outcome studies to validate efficacy and optimize treatment protocols for orthobiologic therapies.

Conclusion

The orthobiologics sector is experiencing transformative growth, powered by innovative therapies, strategic acquisitions, and automated production technologies. Companies such as Isto Biologics and Octane Medical exemplify how regenerative medicine is reshaping orthopedic care, improving patient outcomes, and creating global expansion opportunities. With rising adoption, orthobiologics are poised to become standard practice for bone and cartilage repair in hospitals worldwide.